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Cancer is a leading cause of death in both developed and developing countries.
Although advances in cancer research lead to improved anti-neoplastic therapies,
they continue to have unfavorable outcomes, including poor response and severe
toxicity. Thus, the challenge for the new therapeutic approaches is to increase anti-
tumor efficacy by targeting different molecules encompassed in the tumor and its
microenvironment, as well as their specific interactions. The histamine H4 receptor
(H4R) is the last discovered histamine receptor subtype and it modulates important
immune functions in innate and in adaptive immune responses. Several ligands have
been developed and some of them are being used in clinical trials for immune disorders
with promising results. When searched in The Cancer Genome Atlas (TCGA) database,
human H4R gene was found to be expressed in bladder cancer, kidney cancer, breast
cancer, gastrointestinal cancers, lung cancer, endometrial cancer, and skin cancer. In the
present work, we aimed to briefly summarize current knowledge in H4R’s pharmacology
and in the clinical use of H4R ligands before focusing on recent data reporting the
expression of H4R and its pathophysiological role in cancer, representing a potential
molecular target for cancer therapeutics. H4R gene and protein expression in different
types of cancers compared with normal tissue as well as its relationship with patient
prognosis in terms of survival will be described.
Keywords: histamine H4 receptor, breast cancer, gastrointestinal cancer, melanoma, lung cancer, bladder cancer,
anticancer treatment
INTRODUCTION
Cancer is among the leading causes of death in both developed and developing countries. In 2018,
18.1 million new cancer cases and 9.6 million cancer deaths including non-melanoma skin cancer
were estimated (Bray et al., 2018). Although advances in cancer research lead to improved anti-
neoplastic therapies, they continue to have unfavorable outcomes, including poor response and
severe toxicity. Thus, the challenge for the new therapeutic approaches is to increase anti-tumor
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efficacy by targeting different molecules encompassed in
the tumor and its microenvironment, as well as their
specific interactions.
Remarkable advances have been made in the understanding
of the interactions between immune system and tumor
progression, which paralleled with the development of effective
immunotherapies, including the immune-checkpoint in a variety
of neoplasias (Motz and Coukos, 2013).
Histamine is a biogenic amine with numerous
immunomodulatory roles (Gantner et al., 2002; Medina
and Rivera, 2010; Stark, 2013), being the major mediator
of the acute and chronic inflammatory and the immediate
hypersensitivity responses (Jutel et al., 2009; Stark, 2013).
Histamine acts through four different receptor subtypes: H1,
H2, H3, and H4 receptors (H1R, H2R, H3R, and H4R) (Medina
and Rivera, 2010; Stark, 2013). The H4R is the last discovered
subtype and is mainly expressed in cells of the immune system,
such as mast cells, basophils, eosinophils, monocytes, dendritic
cells, T lymphocytes, and Natural Killer (NK) cells (Stark,
2013; Deiteren et al., 2015; Thurmond, 2015). Its functional
expression is further described in different types of tumors
(Medina and Rivera, 2010; Medina et al., 2013; Cai et al., 2014;
Massari et al., 2017, 2019).
IL-2 immunotherapy and histamine dihydrochloride were
used in numerous clinical trials for the treatment of solid
tumors and hematopoietic cancers with promising outcomes.
Histamine preserved the activity of T lymphocytes and NK
cells by inhibiting the NADPH oxidase-induced formation of
ROS by monocytes/macrophages through the H2R, further
supporting the immunomodulatory role of histamine (Hellstrand
et al., 2000; Agarwala et al., 2002; Asemissen et al., 2005;
Brune et al., 2006; Perz and Ho, 2008; Martner et al., 2010;
Berry et al., 2011; Buyse et al., 2011; Yang and Perry, 2011;
Rydström et al., 2017; Sander et al., 2017; Kiffin et al., 2018). It
is important to highlight that histamine dihydrochloride, used
in combination with IL-2, has been approved in Europe for
the treatment of adults with acute myeloid leukemia (AML)
(Rydström et al., 2017).
Cancer is a complex and highly heterogeneous disease,
representing a challenge for the discovery of biomarkers
to predict treatment response and/or the prognosis of
the pathology, and for the development of targeted
treatments. Drug discovery could be improved by sharing
genomic data sets, which could lead to the identification of
promising novel biomarkers, especially where therapeutic
options are currently lacking. Clinical validation of those
novel cancer biomarkers and treatment strategies is
urgently needed.
Although vast literature can be found describing the use of
H1R and H2R ligands in preclinical and even in clinical studies
(Massari et al., 2019), less data is available regarding the role
of H4R in cancer.
In the present work, we aimed to briefly summarize
current knowledge on H4R pharmacology and H4R ligands
clinical use before focusing on recent data reporting the
expression of H4R and its pathophysiological role in cancer,
representing a potential molecular target for cancer therapeutics.
Furthermore, when available, the relationship between the H4R
expression and patient’s prognosis will be described in different
types of cancers.
H4R PHARMACOLOGY AND CLINICAL
STUDIES
At the beginning of the millennium, the expression of H4R
was described independently by different academic and industry
scientific groups. H4R is a Gαi/o coupled receptor, it is
predominantly expressed in cells of the immune system and it is
particularly involved in immunomodulatory pathways. The main
characteristics of H4R are summarized in Figure 1.
Soon after its discovery, the pharmaceutical industry
attempted to identify the pharmacological profile of H4R in
order to develop selective H4R ligands (agonists or antagonist).
The discovery of the first selective and potent H4R antagonist
JNJ7777120 by Johnson & Johnson Research and Development
(now Janssen Pharmaceuticals, Inc.) was essential for evaluating
the role of H4R in pathophysiology, including immune reaction-
associated pruritus and inflammation (Thurmond et al., 2017).
This compound is the reference tool for studying the functional
activity of H4R and it has been employed in several in vitro
and in vivo studies since its development. However, far from
being an ideal antagonist, it has drawbacks such as short
in vivo half-life and toxicity, which prevented further clinical
studies. Few clinical data are reported on H4R ligands. Only
H4R antagonists are being tested in clinical settings for their
potential therapeutic application in immune-related disorders.
Recently, the compound JNJ39758979 was developed as a more
potent and selective H4R antagonist than JNJ7777120 and it
also shows preclinical anti-inflammatory and antipruritic effects
(Thurmond et al., 2014, 2017). JNJ39758979 exhibited good
preclinical and phase 1 safety in healthy (non-allergic) volunteers
and, therefore, progressed to clinical trials in humans (Kollmeier
et al., 2014; Thurmond et al., 2014). Although it was effective
in reducing pruritus and improving eczema in Japanese adult
patients with atopic dermatitis, it showed agranulocytosis, a
drug associated, life-threatening side effect, which precluded
its clinical use (Thurmond et al., 2014; Murata et al., 2015).
Drug-induced agranulocytosis appeared to be an off-target
effect, likely intrinsic to the chemical structure of the compound
(Thurmond et al., 2014; Murata et al., 2015).
JNJ39758979 was also tested in a phase 2a trial in adults
with uncontrolled asthma without reaching the primary efficacy
endpoint. However, findings suggest a potential effectiveness
in eosinophilic asthma patients. It is important to highlight
that no serious adverse events were reported in this study
(Kollmeier et al., 2018).
To overcome the side effect associated with agranulocytosis,
another H4R antagonist with a different chemical structure
was developed under the name of toreforant (JNJ38518168).
This compound has been safely administered in clinical studies
in patients with rheumatoid arthritis, asthma, and psoriasis
(Thurmond et al., 2017). Although toreforant (30 mg per
day) failed to improve uncontrolled, eosinophilic asthma
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FIGURE 1 | Main molecular and biochemical characteristics of histamine H4 receptor (H4R). GPCR, G protein-coupled receptor; MCP-1, monocyte chemoattractant
protein 1; HMCs, human mast cells; IFNγ, interferon-gamma; NK, natural killer; CNS, central nervous system; cAMP, cyclic Adenosine monophosphate; IP3, inositol
trisphosphate; TGF-β1, transforming growth factor beta 1.
(Kollmeier et al., 2018), its efficacy at 30 and 60 mg was greater
than placebo in patients with moderate-to-severe psoriasis, but
it did not meet the predefined success criterion (Frankel et al.,
2018). In addition, in a phase 2 study, toreforant (100 mg
per day) reduced rheumatoid arthritis signs and symptoms.
However, in phase 2b, no significant improvement was observed
(Thurmond et al., 2016).
A recent phase 2a clinical trial was carried out with the
selective H4R antagonist ZPL-3893787, administered orally
in patients with moderate to severe atopic dermatitis. This
compound further reinforced the antipruritic and anti-
inflammatory effects of H4R antagonists (Werfel et al., 2018;
Schaper-Gerhardt et al., 2019).
As far as we know, until now the clinical use of H4R
ligands in other diseases, such as cancer, is missing and warrants
further investigations.
CLINICOPATHOLOGICAL
CHARACTERISTICS OF H4R IN
GASTROINTESTINAL CANCERS
Gastrointestinal cancer comprises the development of a
neoplastic disease in the organs that form the digestive system
including esophagus, gallbladder, biliary tract, liver, pancreas,
stomach, small intestine, bowel (large intestine or colon and
rectum), and anus. According to the World Health Organization,
colorectal cancer (CRC) and gastric cancer (GC) are the third and
the sixth most common cancers. In addition, CRC, GC, and liver
cancer are the second, third, and fourth most common causes of
cancer death, respectively (Ferlay et al., 2018). Gastrointestinal
malignancies varied in etiology, prognosis, clinical course,
management strategies, and the mainstay of treatment involved
surgery and chemotherapy (Athauda et al., 2019).
We summarize existing preclinical evidences targeting H4R
for gastrointestinal cancer treatment in Table 1.
Cancer of the esophagus, including adenocarcinoma and
esophageal squamous cell carcinoma (ESCC) subtypes, is
the seventh most frequent cancer worldwide and the sixth
most common cause of cancer death with 572,034 new
diagnoses and 508,585 deaths in 2018 (Bray et al., 2018;
Walker and Underwood, 2018). Both histological subtypes
exhibit a poor prognosis with an overall 5-year survival smaller
than 20%, especially in patients with advanced tumor stages
(Bray et al., 2018; Xie and Lagergren, 2018). Therefore, as
for other types of cancer, prevention and early detection are
crucial in reducing cancer burden. Surgical resection and highly
morbid chemotherapy and radiotherapy are the mainstay
treatments for esophageal cancer, which are still associated
with recurrence (Kato and Nakajima, 2013; Chen et al., 2019).
For this reason, further research is necessary to develop more
effective therapeutics.
Several differentially expressed genes in tumor samples
compared to non-tumorigenic tissue could be identified using
data of public profiling arrays. The Cancer Genome Atlas
(TCGA) is a publicly available database that shows the most
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TABLE 1 | Preclinical evidence targeting H4R for gastrointestinal cancer treatment.
Cancer type Experimental model/cells Outcome References
Esophageal cancer Human TE-1, TE-2, TE-3, and TE-13 ESCC cell lines H4R agonist (4-methylhistamine): ↓ proliferation; ↓
invasion; arrest in G0/1 phase; ↓ TGF-β1 expression in
a MAPK- and ACSS2-dependent manner.
He et al., 2018
TE-2 xenograft in mouse 4-methylhistamine: ↓ xenograft tumor growth in vivo
and ↑ survival of tumor-bearing animals.
He et al., 2018
Gastric cancer Human AGS cell line Histamine and clobenpropit: induce G0/G1 phase cell
cycle arrest.
Zhang et al., 2012
Colon cancer Human HT29, Caco-2, and HT116 CRC cell lines H4R antagonist (JNJ7777120): ↓ proliferation; ↓ COX-2
and VEGF expression.
Cianchi et al., 2005
Inflammation-associated CRC in mice H3R antagonist and H4R agonist (clobenpropit): ↓ CRC
carcinogenesis.
Tanaka et al., 2016
Colo-320, Mock-Lovo, and H4R-Lovo CRC cells H4R activation: ↑ expression of p21Cip1 and p27Kip1
proteins, arrest in G0/1 phase through
cAMP/PKA-dependent signaling.
Fang et al., 2011
Pancreatic cancer Human Panc-1 cell line Clobenpropit: ↓ proliferation. Cricco et al., 2004
Human Panc-1, MiaPaCa-2 and AsPC-1 cell lines Clobenpropit: ↓ proliferation. Paik et al., 2014
Panc-1 xenograft mouse Clobenpropit and gemcitabine: ↓ tumor growth. Paik et al., 2014
Liver cancer Human CHOL cell lines Clobenpropit: ↓ proliferation by Ca2+-dependent
pathway and altered EMT and invasion.
Meng et al., 2011
Overexpression of H4R: ↓ proliferation.
Mz-ChA-1 xenograft mouse Clobenpropit: ↓ tumor growth. Meng et al., 2011
ESCC, esophageal squamous cell carcinoma; CHOL, cholangiocarcinoma; ACSS2, acetyl-coenzyme A synthetase 2; CRC, colorectal cancer; EMT, epithelial-
mesenchymal transition.
important genomic changes in tumor tissue and matched normal
tissues from more than 11,000 patients of 33 types of cancers.
Therefore, it notably contributes to accelerate the understanding
of the molecular basis of cancer (Chandrashekar et al., 2017).
Transcriptomic data available in TCGA project were analyzed
using web tools, including UALCAN, cBioPortal, and Firebrowse
portals. UALCAN and Firebrowse obtain RNA-seq data from
primary solid tumors and normal tissue from TCGA. Using these
data, we investigated differences in the H4R gene expression
levels and searched potential correlations of H4R gene expression
and overall survival (OS).
According to the TCGA information, H4R gene expression
is significantly higher in primary tumors when compared with
its expression in normal tissue (Figure 2 and Table 2). In
agreement with these observations, it was recently reported
the expression of H4R not only at the mRNA but also at the
protein level in ESCC. Patients with high protein expression
of H4R in tumor cells exhibited a larger primary tumor
size and a greater number of lymph node metastases than
those with lower expression. The stage of a cancer (I–IV),
based on the AJCC (American Joint Committee on Cancer)
pathologic tumor stage information, describes the size of a
tumor and whether it has spread into nearby lymph nodes
or to other organs (Amin et al., 2017). Kaplan–Meier curves
for patients with AJCC stage III cancer (57 patients) were
further stratified by H4R expression. The median survival rate
was higher for patients with reduced expression of H4R (He
et al., 2018). In contrast, no difference in overall survival
(OS) was observed in TCGA probably because Kaplan–Meier
curves include all stages and both histological esophageal cancer
types (Table 2).
Preclinical data show that H4R activation using the H4R
agonist 4-methylhistamine not only blocked cell cycle,
proliferation, and invasion of ESCC cells, but also reduced
TE-2 tumor xenografts and increased the survival of tumor-
bearing mice (Table 1), which suggests that H4R could be a target
for ESCC treatment (He et al., 2018).
At early stages gastric cancer is almost a curable malignancy;
however, most of the patients are diagnosed at advanced stages,
which shows a poor 5-year survival rate (Dicken et al., 2005;
Bray et al., 2018). While treatment modalities include surgery
and chemotherapy (Song et al., 2017), little is known about the
participation of H4R in gastric cancer.
According to TCGA data, H4R expression level is reduced in
primary tumor samples compared with normal tissue (Figure 2
and Table 2). Previous data showed, in gastric cancer samples
obtained from 131 Chinese surgical patients, a down-regulation
of H4R in gastric carcinomas especially for cancer stage 3 and
4 compared to the adjacent normal tissue, which suggest that
H4R plays a role in histamine-mediated growth control of gastric
cancer cells. Furthermore, authors demonstrated that deletion
and downregulation of H4R gene take place in the progression
but not the initiation of stomach cancer (Zhang et al., 2012).
As it was observed in ESCC, H4R agonists (histamine and
clobenpropit) reduced growth and induced G0/G1 cell cycle
arrest in AGS cell line (Zhang et al., 2012), (Table 1).
For both sexes combined CRC is the third most commonly
diagnosed and the second most common cause of death by
cancer worldwide, with extensive geographical variation in
incidence and mortality (Bray et al., 2018; Pilleron et al., 2019).
Although frequently combined with colon cancer (as CRC),
rectal cancer accounts for one-third of CRCs and is particularly
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FIGURE 2 | Analysis of H4R gene expression in different types of human cancers. Box plots show H4R expression levels measured as log2 RSEM (RNA-Seq by
Expectation Maximization) from tumor (red box) and normal tissue (blue box). RNA-seq data was obtained from TCGA samples and analyzed using Firebrowse web
resource (http://firebrowse.org, Deng et al., 2017). BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; COADREAD, colorectal adenocarcinoma;
ESCA, esophageal carcinoma; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung
adenocarcinoma; LUSC, lung squamous cell carcinoma; PAAD, pancreatic adenocarcinoma; UCEC, uterine corpus endometrial carcinoma. Additional statistical
parameters are displayed in Supplementary Figure S2.
TABLE 2 | Differential expression of H4R in cancer.
Cancer type H4R expression in tumor
vs. normal tissue∗
Overall survival with high
H4R expression∗





Gastrointestinal cancer Colon cancer ↓ (P < 0.05) NS 0.772 0.78%
Pancreatic cancer NS ↑ (P = 0.05) ND 9.68%
Esophagus cancer ↑ (P < 0.05) NS 1.090 8.06%
Stomach cancer ↓st2, ↑ st3 (P < 0.01) NS 0.950 5.44%
Liver cancer ↑ (P < 0.05) NS 1.080 0.45%
Urogenital cancer Bladder urothelial
carcinoma
↓ (P < 0.05) NS 0.406 2.91%
Kidney renal clear cell
carcinoma
↑ (P < 0.001) ↓ (P = 0.034) 1.840 0.74%
Kidney renal papillary
cell carcinoma
NS NS 1.630 0.34%
Uterine corpus
endometrial carcinoma
↓ (P < 0.01) ↓ (P = 0.0037) 0.909 2.19%
Lung cancer Lung adenocarcinoma NS NS 0.836 3.24%
Lung squamous cell
carcinoma
↓ (P < 0.01) NS 0.577 4.31%
Breast cancer Breast invasive
carcinoma
↓ (P < 0.001) NS 0.465 1.27%
∗http://ualcan.path.uab.edu Additional information is displayed in Supplementary Figure S1. ∗∗http://firebrowse.org Additional information is displayed in
Supplementary Figure S2. #http://www.cbioportal.org Additional information is displayed in Supplementary Figure S3. NS, not significant; ND, not determined.
challenging with regard to treatment strategies and outcomes
(Tamas et al., 2015). Treatment for CRC is based largely
on the cancer stage (extent) and the implementation of
novel treatment modalities have significantly improved the
management of CRC, with surgery remaining as the main
pillar. Radiation and chemotherapies may also be used
before or after surgery (Banerjee et al., 2017; Ratnapradipa
et al., 2017; São Julião et al., 2017), while immunotherapy
arises as a novel promising therapeutic approach for this
pathology (Gutting et al., 2018). The role of histamine
and histamine receptors in this cancer subtype has been
more extensively investigated than in gastric, esophageal
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or liver cancer (reviewed in Medina and Rivera, 2010;
Massari et al., 2019).
By means of TCGA genomic data, we demonstrated that
H4R gene expression is significantly reduced in primary colon
tumors compared with normal colon tissue (Figure 2 and
Table 2, Massari et al., 2019). Rectal cancer samples followed
the same expression pattern. Accordingly, it was previously
demonstrated the protein expression of H4R in human CRC
cell lines and tissue that further confirmed the down-regulation
of H4R expression observed in tumor samples compared to
normal colonic tissue (Boer et al., 2008). In line with these
results, Fang et al. (2011), showed reduced expression of H4R
in advanced CRC compared with those in an initiating stage.
These authors also showed that H4R activation using agonists
in CRC cell line overexpressing H4R resulted in reduced growth
and progression (Fang et al., 2011) (Table 1). On the other hand,
a previous study showed that JNJ7777120 inhibited histamine-
induced cell growth of human CRC cell lines (Cianchi et al.,
2005). However, a newer study showed again that H4R activation
with the H3R antagonist/H4R agonist clobenpropit reduced
CRC inflammation-associated carcinogenesis (Tanaka et al.,
2016). Further in vitro and in vivo studies with specific H4R
compounds should be designed to confirm the anti-tumoral
effects of H4R agonists.
In addition, it was reported that histidine decarboxylase
(HDC) deficiency promoted inflammation-associated CRC.
Exogenous histamine administration induced differentiation
of CD11b+Gr-1+ immature myeloid cells and suppressed
their ability to support the tumor growth (Yang et al., 2011).
Furthermore, more recently, Gao et al. (2017), showed that
histamine produced by the gut microbe hdc+ Lactobacillus
reuteri, histamine-producing probiotic, reduced chronic
intestinal inflammation and colorectal tumorigenesis in
Hdc−/− mice. Administration of L. reuteri and not of an
isogenic HDC-deficient L. reuteri mutant that was unable to
generate histamine, suppressed carcinogenesis, cancer-associated
cytokines, and decreased the relative number of splenic
CD11b+Gr-1+ immature myeloid cells, which confirmed the
potential antitumorigenic effect of histamine (Gao et al., 2017).
Liver cancer is the sixth most commonly diagnosed cancer and
the fourth leading cause of cancer death worldwide in 2018, with
about 841,000 new cases and 782,000 deaths annually (Bray et al.,
2018). Primary liver cancer includes hepatocellular carcinoma
(HCC) (comprising 75–85% of the cases) and intrahepatic
cholangiocarcinoma (CHOL, comprising 10–15% of the cases)
as well as other rare types. Chronic infection with hepatitis B
or C virus, alcohol abuse, liver cirrhosis, aflatoxin-contaminated
foodstuffs are main risk factors for HCC (Thun et al., 2010; Bray
et al., 2018). At diagnosis, almost 70% of the patients have only
access to a palliative treatment (Llovet et al., 2016). Treatments
include surgery, sorafenib as first-line therapy (Llovet et al.,
2008) and regorafenib as second-line treatment, both drugs with
modest OS benefit (Bruix et al., 2017; Roth and Decaens, 2017).
Prognosis of CHOL is also considered dismal and the majority
of patients are diagnosed at late stages of the disease. Surgical
treatment, whenever possible, is the only potentially curative
therapeutic option for CHOL (Blechacz, 2017).
Few studies show the participation of histamine in biological
processes associated to liver carcinogenesis or demonstrated the
expression of the four histamine receptor subtypes. Histamine
seemed to produce a dual effect on proliferation in both HCC
and CHOL depending on the receptor involved (for review
Massari et al., 2019). Analyses of TCGA cancer genomics data
show a modest but significant increase in the expression of H4R
levels in HCC primary tumors compared with normal tissue
(Figure 2 and Table 2). Immunohistochemical studies in patient
samples are needed to confirm these differences at the H4R
protein level. Similarly, H4R gene expression in CHOL primary
tumors (n = 36) is slightly increased compared to normal tissue
(n = 9) (Massari et al., 2019). In line with these observations,
it was shown that H4R immunoreactivity in human CHOL
specimens is increased compared with non-malignant tissues
(Meng et al., 2011).
Consistent with the results in CRC and pancreatic cancer
models, the H3R antagonist/H4R agonist clobenpropit inhibited
human CHOL proliferation, decreasing tumor invasion and
growth through disruption of the epithelial-mesenchymal
transition (EMT) using in vitro and in vivo model systems. To
confirm the exclusive participation of the H4R in these processes,
studies were performed in cells with genetic knockdown of the
H3R and overexpression of H4R (Meng et al., 2011). Further
studies are necessary to fully understand the role of histamine and
H4R in liver cancer progression.
Pancreatic cancer remains the seventh leading cause of
cancer-related mortality in both males and females (Bray et al.,
2018). Although surgery remains the only curative treatment
for pancreatic cancer, most of the patients have unresectable
disease and approximately 80% patients who undergo curative
intent surgery ultimately relapse. The standard of care is
chemotherapy; however, it constitutes a relatively chemotherapy-
resistant cancer. All of these characteristics, together with the
propensity to metastasize early in the course of disease, predict
its poor prognosis (Diab et al., 2018; Young et al., 2018).
As in liver cancer, histamine seems to produce a dual effect on
proliferation depending on the histamine receptor subtype that
is activated. The presence of H4R was reported in three human
pancreatic cell lines (Panc-1, MiaPaCa-2, and AsPC-1) (Cricco
et al., 2008; Paik et al., 2014). In these cell lines, clobenpropit
inhibited cell proliferation and cell migration, disrupting ETM.
Combination therapy of clobenpropit and gemcitabine reduced
tumor growth and enhanced apoptosis in Panc-1 xenograft
induced in mice (Paik et al., 2014).
Although not significant, probably due to the reduced number
of samples, H4R gene expression in pancreatic primary tumors
(n = 178) seems to be decreased compared to normal tissue (n = 4)
by means of TCGA database and UALCAN web portal (Table 2
and Supplementary Figure S1). Immunohistochemical studies in
a large number of patient specimens are still missing and should
be investigated. It is important to highlight that high expression
of H4R in tumor specimens was associated with increased OS in
pancreatic cancer (Table 2). In contrast, no significant difference
in OS between low/medium H4R expression level and high H4R
expression level tumor samples was observed using TCGA data
in other gastrointestinal cancers (Table 2).
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Described evidence indicate that H4R expression is modulated
in different gastrointestinal cancers. The expression of the H4R
seems to be reduced in human CRC and GC and increased
in ESCC, CHOL, and liver cancer compared to normal tissue.
Also, it could vary between early and advanced stages, which
suggests the participation of H4R in the carcinogenesis process.
This deserves further investigation in order to deeply understand
the role of H4R in cancer development and progression in
view of identifying a novel therapeutic target or even a useful
prognostic biomarker.
H4R EXPRESSION IN URINARY TRACT
CANCERS
The predominant urinary tract malignancies are bladder
and kidney cancer (Yaxley, 2016). Despite advances in
prevention, detection, and therapeutics, the incidence
of age-related cancers of the urinary system is probably
increasing as a result of population aging (Golabek et al., 2015;
Bray et al., 2018).
Bladder cancer is the most common malignancy in the urinary
system and is the 10th most common form of cancer worldwide.
Interestingly, bladder cancer is more frequent in men than in
women, with respect to incidence and mortality rates (Bray et al.,
2018). Most cases are bladder urothelial carcinomas (BLCA),
which often appear as superficial papillary tumors with good
prognosis and surgery as a primary treatment. However, muscle-
invasive carcinomas are presented in about thirty percent of cases,
having a higher risk of metastasis development and may need
cystectomy and adjuvant chemotherapy (Jimenez-Guerrero et al.,
2018; Li et al., 2018).
The most common type of kidney cancer is called renal
cell carcinoma. An estimated 65,340 cases were expected to
have been diagnosed in 2018 and an estimated 14,970 to
have died of this cancer (Bray et al., 2018). TCGA analysis
shows two subtypes called kidney clear cell carcinoma (KIRC),
which represents approximately 92 percent of such cases, and
papillary carcinoma (KIRP). KIRC is associated with resistance
to radio and chemotherapy, and with poor OS, particularly for
patients with late-stage disease. As in other types of cancers,
early detection of kidney cancer favors an effective treatment.
Standard surgical resection is used for localized tumors. Patients
with metastatic cancer benefit from chemotherapy based on the
tyrosine kinase inhibitor (e.g., cabozantinib, sunitinib) (XIao
et al., 2018; Yu et al., 2018).
As previously indicated, numerous studies show that
histamine and H4R are involved in cell proliferation, a key event
in tumor development and progression, in different types of
tumors. However, to the best of our knowledge, a comprehensive
investigation of whether H4R is involved in the carcinogenesis of
the urinary system has not yet been performed.
Similar to what was previously demonstrated in CRC, TCGA
data showed attenuated H4R gene expression in human BLCA
specimens compared to normal tissue (Figure 2, Massari
et al., 2019). No significant differences were observed between
low/medium or high expression at least in OS (Table 2). On the
other hand, as it was observed in ESCC and liver cancer, KIRC
and KIRP exhibited increased H4R gene expression compared to
normal tissue (Figure 2 and Table 2). KIRC patients with high
expression levels of H4R show a significant reduced OS compared
with the ones with low/medium expression (Table 2). Future
research should study the potential association of H4R expression
and clinicopathological characteristics in human specimens of
tumors of the urinary tract, of different stages and histological
types, to confirm the potential role of H4R as a prognostic
biomarker of these malignancies.
In addition, studies in experimental tumor models are
necessary to determine the potential therapeutic value of H4R in
bladder and/or kidney cancers.
H4R EXPRESSION IN GYNECOLOGICAL
AND BREAST CANCER
Breast cancer is the most frequently diagnosed neoplasia and
the leading cause of cancer death in women worldwide.
Incidence rates of breast cancer have been continuously
rising in most countries (Bray et al., 2018). The cancer
of the breast is a heterogeneous disease, showing different
histological types, molecular profile and clinical response to
therapy. Depending on the presentation and the molecular and
histological characteristics, treatments include surgery, radiation
therapy, chemotherapy, and targeted molecular treatments
(Nagini, 2017).
Histamine plays a critical role in physiological conditions of
the mammary gland as well as in breast cancer. Numerous studies
reported the expression of the four histamine receptors and show
that all of them are implicated in biological processes associated
to breast cancer (Martinel Lamas et al., 2015c; Massari et al.,
2019). Since the first description of the H4R, new functions for
this receptor are continuously discovered.
The first description of H4R in cancer was reported in
breast tumors. H4R is expressed at the protein and mRNA
level in malignant lesions of the human mammary gland and
in MDA-MB-231 and MCF-7 breast cancer cell lines (Medina
et al., 2006, 2008). These results are consistent with findings
from TCGA data in a large number of human samples. H4R
gene is expressed in primary tumors and its expression is
significantly reduced compared with normal tissue (Massari et al.,
2019, Figure 2). However, no significant changes were observed
between low/medium or high expression at least in OS (Table 2).
Further supporting the critical role of H4R in breast cancer
development and progression, He and coworkers demonstrated
the presence of polymorphisms of the H4R gene (rs623590,
rs11662595, and rs1421125 genotypes of H4R gene) in Chinese
Han population, which were associated with the risk of
developing breast cancer and the malignant degree of the tumor
(He et al., 2013).
A summary of preclinical evidences targeting H4R in
breast cancer is depicted in Table 3. All the studies, using
different H4R ligands and also genetic down-regulation of
H4R, demonstrated that the principal receptor subtype involved
in the histamine-induced reduction of proliferation was the
Frontiers in Pharmacology | www.frontiersin.org 7 June 2019 | Volume 10 | Article 556
fphar-10-00556 June 4, 2019 Time: 16:22 # 8
Nicoud et al. H4R a New Target in Cancer Treatment
TABLE 3 | Preclinical evidence targeting H4R for the treatment of melanoma, breast, lung, and testicular cancers.
Cancer type Experimental model/cells Outcome References
Lung Cancer Human NSCLC cell lines and xenograft
NSCLC tumors
H4R agonist (4-methylhistamine): ↓tumor volume, ↑
survival, ↑ E-cadherin and ↓ vimentin (↓ EMT
progress).
Cai et al., 2014
Breast cancer Human MDA-MB-231 and MCF-7 cell
lines
H4R agonists (histamine, clobenpropit, VUF8430):
↓ proliferation; ↑ apoptosis; ↑ senescence; cell
cycle arrest.
Martinel Lamas et al., 2013;
Medina et al., 2008, 2011
MDA-MB-231 xenograft in mouse H4R agonists (histamine, JNJ28610244): ↓ tumor
volume; ↓ angiogenesis. Histamine: ↑ survival.
Martinel Lamas et al., 2013,
2015a
Melanoma Human WM35 and M1/15 cell lines H4R agonists (Clozapine, VUF8430): ↓ proliferation,
↑ senescence, inhibited forskolin-induced cAMP
levels in M1/15, increased phosphorylation levels of
ERK1/2 in both cell types.
Massari et al., 2013
Human 1205Lu cell line H4R agonists (histamine, Clozapine,
JNJ28610244): ↓ proliferation, ↑ senescence, ↑
melanogenesis.
Massari et al., 2017
M1/15 xenograft in mouse Histamine and clozapine: ↓ tumor volume, ↑
survival.
Massari et al., 2013
1205Lu xenograft in mouse H4R agonists (histamine, Clozapine,
JNJ28610244): ↓ tumor growth, ↓ mitotic index,
and PCNA in tumor, ↓ metastatic spread, and
angiogenesis.
Massari et al., 2017
Testicular cancer Mouse MA-10 cell line H4R agonists (JNJ28610244 and VUF8430): ↓
proliferation, VUF8430: ↓ LH/hCG-stimulated
cAMP production and ↓progesterone production.
Abiuso et al., 2014
Rat R2C cell line H4R agonist (VUF8430): ↓ proliferation, ↓
steroidogenesis, ↓ pro-angiogenic capacity.
Abiuso et al., 2018
EMT, epithelial to mesenchymal transition; LH/hCG, luteinizing hormone/choriogonadotropin receptor; NK, natural killer; NSCLC, non-small cell lung cancer; OTSCC, oral
tongue squamous cell carcinoma; PCNA, proliferating cell nuclear antigen.
H4R (Medina et al., 2008; Martinel Lamas et al., 2013). The
in vivo administration of histamine or H4R agonists (e.g.,
JNJ28610244) diminished the tumor growth of human triple
negative breast cancer (TNBC) developed in immune-deficient
nude mice with MDA-MB-231 cells (Martinel Lamas et al.,
2013, 2015b). On the other hand, tumor doubling time was
not significantly modified while mean survival was reduced
after the treatment with the H4R antagonist JNJ10191584
(Martinel Lamas et al., 2013).
In the same model, histamine administration was
demonstrated to potentiate ionizing radiation and doxorubicin
therapies (Martinel Lamas et al., 2015a,b,d).
Considering the pleiotropic nature of histamine actions
and its numerous immunomodulatory roles, recently it
was demonstrated a novel role of H4R in the antitumor
immunity of breast cancer (Sterle et al., 2019). The study
was performed in a model of TNBC developed orthotopically
with 4T1 cells in H4R KO compared with wild type mice
and no treatments were used. Mice lacking H4R show
reduced tumor growth and percentage of CD4+ tumor-
infiltrating T cells together with increased infiltration of
natural killer (NK) cells (Sterle et al., 2019). These findings
highlight the critical interplay between tumor cells and host
immune cells, which could determine the clinical therapeutic
outcomes of a pharmacological compound. Therefore, it is
important to validate the potential use of H4R ligands in
immunocompetent hosts.
Gynecologic cancer is the fourth most common cancer in
women and 1 in every 20 women is estimated to develop
gynecologic cancer in their lifetime. The main types are ovarian,
cervical, uterine, vaginal, and vulvar. Each of these cancers have
different disease evolution, prevention strategies, and therapies.
Cancer of the corpus uteri is usually indicated as endometrial
cancer, which is a common gynecological malignancy. Although
the overall prognosis is relatively good, high-grade tumors
tend to recur. Standard treatment consists of hysterectomy and
bilateral salpingo-oophorectomy while combination of surgery
and chemotherapy is employed in advanced disease (Bartosch
et al., 2011; Amant et al., 2018).
It was previously reported that histamine and polyamines are
increased in human ovarian, cervical and endometrial cancer in
comparison with normal tissues (Chanda and Ganguly, 1995).
However, little is known about the expression of histamine
receptors and their role in tumorigenesis.
Although mRNA expression of H1R and H2R was shown,
the expression of H3R and H4R was hardly detected in HEC-1
endometrioid adenocarcinoma cells. Histamine through the H1R
increased aldehyde dehydrogenase 1 high population, a marker
of cancer-initiating cells, which was associated to histamine-
induced invasiveness and drug resistance (Wang et al., 2014).
UALCAN and Firebrowse analyses of TCGA data indicated
that H4R expression levels are reduced in samples of
uterine corpus endometrial carcinoma (UCEC) compared
to non-malignant tissue, in particular in endometrioid cancer,
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the most common type of endometrial cancer (Figure 2
and Table 2). Furthermore, patients with tumors showing
low/medium H4R expression presented a higher OS compared
to those with high expression levels (Table 2).
Further studies are needed to validate the potential
of H4R targeted therapy in the treatment of breast and
gynecological cancers.
H4R EXPRESSION AND LUNG CANCER
Worldwide, lung cancer is the most commonly diagnosed
cancer and the leading cause of cancer death in both sexes
combined (Bray et al., 2018). Non-small cell lung cancer
(NSCLC) is the most common form of lung cancer and
comprises adenocarcinoma (LUAD), squamous cell carcinoma
(LUSC), and large cell carcinoma (Stoyanov et al., 2012).
Therapeutic approaches strongly depend on cancer stage.
Surgery is the recommended treatment for patients with
stages I–II NSCLC (Vansteenkiste et al., 2014). For patients
with clinical stage I NSCLC with unresectable lesions, high-
dose stereotactic body radiation therapy is recommended. The
standard of care for patients with locally advanced NSCLC
is thoracic radiotherapy with the concurrent chemotherapy
and for patients with advanced NSCLC who do not fit an
approved molecular targeted therapy, the standard first-line
treatment remains to be chemotherapy. In addition, early
clinical trials with immunotherapy with monoclonal antibodies
directed to the PD-1 receptor or its ligand PD-L1 have shown
durable responses in about 14–20% of patients with advanced
NSCLC (Hirsch et al., 2017). In spite of the advances in
novel therapeutics, lung cancer continues leading the rank
of cancer death worldwide. Therefore, the development of
novel safe and effective molecular targeted therapy is a
critical unmet need.
Previous reports suggested the involvement of histamine
metabolism and mast cells in the pathogenesis of lung cancer
(Stoyanov et al., 2012; Medina et al., 2013; Massari et al., 2019).
Histamine plasma levels are decreased in cancer patients (Della
Rovere et al., 2006) and the H4R seems to play a critical
role in NSCLC progression through preventing EMT progress
(Cai et al., 2014).
According to genomic data from TCGA, H4R gene expression
is significantly reduced in both LUAD and LUSC compared
to normal tissue samples (Figure 2 and Table 2), although
no significant differences were observed in OS rates in none
of the cancer types (Table 2). Likewise, results described in
breast cancer, genetic variations of H4R gene were found in
a large number of Chinese NSCLC patients. In particular,
the loss-of-function polymorphism rs11662595, associated to
a higher invasive behavior, was linked to the prognosis, the
degree of malignancy, and the metastatic potential of NSCLC
(Cai et al., 2017).
In this sense, treatment with 4-methylhistamine H4R
agonist reduced aggressive potential in both NSCLC
cell lines and xenograft NSCLC tumors (Cai et al.,
2014), (Table 3).
H4R EXPRESSION IN MELANOMA AND
OTHER CANCERS
It is well known that histamine regulates physiological and
pathological conditions not only of the skin (Gutzmer et al., 2011;
De Benedetto et al., 2015; Lin et al., 2015) but also of numerous
organs (Massari et al., 2019). Apart from the cancer types
described above, histamine is a crucial modulator of proliferation
in other types of tumors, including melanoma and head and neck
cancers (Massari et al., 2019).
The incidence and mortality rates of cutaneous melanoma,
the deadliest and more aggressive type of skin malignancy, are
continuously increasing worldwide (Ingraffea et al., 2012; Bray
et al., 2018). Although novel oncogene-targeted therapy and
immune checkpoint blockade have shown some efficacy, the
clinical benefit in terms of disease-free interval is of only a
few months. Therefore, the study of new therapeutic targets is
imperative (Block et al., 2015; Marzuka et al., 2015; Bernatchez
et al., 2016; Prieto et al., 2016).
Previous findings demonstrated the functional expression
of H4R in human melanoma cells and also the presence of
H4R in melanoma specimens. H4R expression level in benign
lesions of the skin was significantly higher than in malignant
tissues. In melanoma samples, H4R immune-expression was
inversely correlated with PCNA expression and mitotic index,
both proliferation and prognostic markers (Massari et al., 2017).
In agreement with these results, administration of histamine
and H4R agonists led to a significant reduction of proliferation
and metastatic spread in vitro in different human tumor cell lines
and in vivo in human 1205Lu tumor developed in nude mice
(Massari et al., 2011, 2013, 2017), (Table 3).
Last but not least, a recent work in Leydig-cell tumors
(LCT), which are rare testicular endocrine tumors shows that
H4R agonist VUF8430 treatment inhibited steroidogenesis and
proliferation in R2C cells and also reduced pro-angiogenic
capacity both in vitro and in vivo. Furthermore, H4R
immunostaining was weak in LCT but moderate/strong in
normal prepubertal testes (Abiuso et al., 2014, 2018).
We were not able to compare the H4R expression levels
between normal and tumor tissue, for melanoma or testicular
cancer, due to the absence of non-malignant tissue expression
levels using TCGA data.
Further studies are needed to corroborate the potential of H4R
as a target for the treatment and also to determine whether the
evaluation of H4R expression could be useful as a prognostic
biomarker of these malignancies.
A summary of preclinical evidences targeting H4R for the
treatment of melanoma and testicular cancer is shown in Table 3.
LIMITATIONS OF H4R TRANSLATIONAL
RESEARCH
Numerous preclinical data derived from in vitro and in vivo
experimental models of cancer together with studies of human
normal and tumorigenic tissues demonstrated undoubtedly the
participation of H4R in cancer progression and suggest the use
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of H4R ligands in the molecular targeted therapy of cancer.
Improvement and validation of H4R targeting compounds
should be considered before moving to clinical trials.
One issue is the lack of selectivity of some H4R ligands
based, at least in part, in the high structural homology between
H3R and H4R. Therefore, many imidazole-containing H3R
ligands, have significant affinity for the H4R, including (R)-
α-methylhistamine, imetit, and clobenpropit, which all act as
agonists at the H4R. The antipsychotic drug clozapine has affinity
for other GPCRs but also exhibits H4R agonist activity.
Nonetheless, changing the structure of some compounds
increased specificity. This is the case of VUF8430, a full agonist of
the H4R with around 30-fold selectivity over the H3R. One of the
most selective H4R agonist currently reported is the compound
4-methylhistamine, with more than 100-fold selectivity over the
other 3 histamine receptor subtypes (Leurs et al., 2009; Lim et al.,
2009; Panula et al., 2015).
As in the case for agonists, the first antagonists for H4R
were mostly H3R antagonists. With time, though, more selective
inhibitors were developed. Antagonist JNJ7777120, as mentioned
before, shows high selectivity for the human, mouse and rat H4R.
Also, it has been used extensively as the reference compound
to determine the role of H4R antagonism in a variety of
experimental animal models of disease (Stark, 2013; Panula et al.,
2015). Based on JNJ7777120 structure, diverse compounds have
been synthesized such as VUF6002, also known as JNJ10191584.
Most of these agonistic and antagonistic compounds were
employed to assess the pathophysiological role of H4R in
different types of cancer.
Another issue is the fact that different H4R species orthologs
could exhibit different pharmacological properties and some
H4R ligands exhibited biased signaling for both the G protein
and β-arrestin pathways, adding complexity to the H4R
pharmacology (Seifert et al., 2011; Nijmeijer et al., 2012; Stark,
2013; Panula et al., 2015).
The evidence mentioned above could explain some
discrepancies observed between in vivo and in vitro findings
using H4R compounds. Therefore, the use of a combination of
pharmacological tools including agonist and antagonist, genetic
modulation of H4R expression and the use of H4R KO mice
when possible, could help to better interpret results.
In addition, the contribution of genetic and post-
transcriptional variations should be considered in the
experimental outcomes with H4R ligands. Human H4R isoforms
are the result of alternative splicing. Shorter isoforms do not
bind histamine or inverse agonists and at least in heterologous
expression systems, they could produce dominant negative
effects on the full-length isoform (van Rijn et al., 2008; Panula
et al., 2015), suggesting that they may elicit modulatory effects
on H4R signaling. The expression of different isoforms in cancer
cells and their pathophysiological relevance are still unknown
and should be evaluated in future studies.
Some polymorphisms of H4R have been reported in cancer,
which were associated to malignancy of the disease in a Chinese
Han population. Further studies are needed to corroborate
these in other populations in order to evidence whether they
are ethnicity-based genetic variations that could influence H4R
FIGURE 3 | Alteration frequency of H4R gene in the main cancer types. The
alterations include deletions (blue), amplification (red), multiple alteration (gray),
and mutation (green). Data was obtained from cBIOPortal web resource
(http://www.cbioportal.org/, Cerami et al., 2012; Gao et al., 2013). Lung squ,
lung squamous cell carcinoma; Lung adeno, lung adenocarcinoma; ccRCC,
kidney renal clear cell carcinoma; pRCC, kidney renal papillary cell carcinoma.
Additional statistical parameters are displayed in Supplementary Figure S3.
ligands’ effects (He et al., 2013; Micallef et al., 2013; Cai et al.,
2017). In addition, the study of the alteration frequency of
H4R gene in the main cancer types, with available data from
cBioPortal, indicated that H4R gene alterations occurred in
different percentage depending on cancer type. Amplifications
and mutations comprised the major types of H4R gene alterations
(Figure 3). The significance of the genomics alterations of H4R in
cancer tissue is still unknown and deserves further investigation.
Last but not least, uncertainties around the selectivity of
antibodies used to detect H4R have been reported. Suppliers
should improve specificity validation of commercially available
antibodies prior to their release to the market. It was recently
reported four criteria of which at least one has to be
fulfilled to provide evidence for the specificity. They include
the use of cells from receptor KO animals, receptor-selective
siRNA treated cells, cells transfected with the targeted and
non-targeted related receptors or use of various antibodies
directed against different epitopes of the receptor (Miyauchi
et al., 2009; Beermann et al., 2012; Gutzmer et al., 2012;
Seifert et al., 2013).
CONCLUSION
According to estimates from the World Health Organization,
cancer incidence and mortality are rapidly increasing worldwide.
Cancer is expected to rank as the leading cause of death in
the 21st century (Bray et al., 2018). Despite the advances in
cancer clinical research, including novel molecular targeted
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therapies and immunotherapy, and the aggressiveness or even
multiple therapeutics employed to treat cancer, a high percentage
of oncological patients will suffer from overwhelming morbi-
mortality, indicating a clear unmet therapeutic need to improve
patient survival and quality of life.
A precise and accurate translational cancer research is
essential for the development of novel therapeutic agents. In
this sense, the use of public genomic data has enormously
contributed to expanding our understanding of cancer biology
especially in terms of evidencing differences between normal
and malignant samples. This could help to develop more
specific and less toxic molecular targeted therapies for cancer
treatment. In this context, the publicly available TCGA dataset
is extremely useful.
The immunohistochemical studies together with the H4R
gene expression data from TCGA database and UALCAN and
Firebrowse web portals provided consistent evidence showing
that H4R is differentially expressed in primary tumors compared
with normal tissue, suggesting a crucial role of this histamine
receptor subtype in carcinogenesis. The expression of H4R
is associated with some clinicopathological features, including
cancer stage and survival depending on the cancer type.
H4R gene expression is reduced in CRC, GC, breast cancer,
LSCC, and also bladder urothelial carcinoma, and uterine
corpus endometrial carcinoma, while is increased in liver,
esophageal and kidney cancers compared to normal tissue.
Presented data supported previous findings of H4R expression
impairment in cancer, which could influence the histamine-
induced growth modulation in cancer cells, suggesting a potential
role of abnormal H4R expression in cancer progression. The
mechanisms responsible for the differential up or down-
regulation of H4R in different cancers are unknown and deserve
further investigation. In this context, H4R gene alterations (e.g.,
mutation, deletions, and amplifications) in different cancer types
should be studied.
According to TCGA database, the gene expression
profiles are obtained from primary solid tumors. Thus,
we have to consider the cellular source of H4R expression
in tumors. They comprise epithelial tumor cells and cells
of the tumor microenvironment including infiltrating
immune cells and endothelial cells that could also expressed
H4R. Therefore, results of H4R gene expression should
be confirmed by means of other methodologies including
immunohistochemical studies in which not only the H4R
protein expression but also the receptor-expressing cell type
could be identified.
In this regard, numerous studies of the H4R protein
expression and its localization have already been performed in
different types of cancers including ESCC, GC, CRC, CHOL,
breast cancer and melanoma (Medina et al., 2008; Fang et al.,
2011; Meng et al., 2011; Zhang et al., 2012; Wang et al.,
2014; Massari et al., 2017; He et al., 2018). Research data
demonstrated the H4R positive immunoreactivity, especially in
cancer epithelial cells. In most cases, differential expression
of H4R between normal and malignant tissue assessed by
immunohistochemistry was in accordance with the TCGA H4R
gene expression.
It is important to point out that the specificity of the
commercial H4R antibodies is a concern considering the
non-specific binding effects. There are four different criteria
to check the specificity of an antibody including the use
of knockout cells, genetic knockdown of the expression in
cells, cells recombinantly expressing closely related receptor
subtypes, in which the reactivity of a specific antibody have
to markedly decrease for genetic knockdown approach or
be absent for the others (Seifert et al., 2013). Another
criterium is the use of additional antibodies recognizing different
epitopes but producing comparable results. In the latter, the
presence of H4R splice variant isoforms, gene alterations
and post-translational modifications should be considered in
the analysis. Anyway, in most reported cases some efforts
were made to check specificity of the H4R antibody, which
include use of siRNA for H4R down-regulation, cells that
do not expressed H4R and other methodologies such as
Western blotting, FISH.
In addition, H4R expression was associated to prognosis
in terms of OS in some cancer types, suggesting that H4R
might represent a novel potential prognostic biomarker,
which could complement routine histopathological analysis
for some cancer types. Further immunohistochemical
studies in a large number of patients’ tumor samples using
antibodies with validated specificity should be dedicated to
carefully defined the association between H4R expression and
cancer prognosis.
Considering the potential different expression according
to race, gender, and age, generalization of results should
be avoided. Some of the studies investigating the H4R
positive immunoreactive cancer cells and also the presence of
polymorphisms of H4R were performed in Chinese population
and therefore the level of H4R expression and the presence
of H4R polymorphisms should be also corroborated in
other ethnic groups.
A comprehensive study of H4R isoforms and their associated
signaling pathways should be performed in different cancer types
in order to evaluate whether a particular isoform is modulated
by therapeutics or is involved in cancer progression. In this
sense, pharmaceutical efforts could be focus in the development
of drugs targeting specifically an isoform or selectively a signal
transduction pathway.
H4R ligands exhibit a complex pharmacology, which is
related to numerous factors including tissue variability in
histamine-induced signaling pathways, functional selectivity,
intra and interspecies differences in potency and selectivity,
structural homology with H3R, splice variant isoforms, and
polymorphisms that could preclude H4R function, together with
impairment expression in pathological conditions. Therefore,
a careful interpretation of H4R ligands’ effects in vivo
should be performed.
Evidence from independent research groups support the
introduction of highly potent and selective H4R agonists
activating signal transduction pathways in tumor cell types that
could contribute to advance in current tumor therapy paradigms
in terms of a targeted therapy. However, although all preclinical
studies that were performed using H4R agonists revealed a
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clear antitumor effect associated to reduced tumor growth
and, in some cases, metastatic potential, they were carried
out in immunodeficient hosts, in which the role of the
immune system in the response to therapeutics could not
be evaluated. One of the major impediments in the bench-
to-bedside progress is the use of trustful mouse models that
recapitulate the complexity of human cancer and immune
population within the tumor microenvironment. Considering
the notable involvement of H4R in immunomodulation, it
is imperative to validate the therapeutic efficacy globally,
considering the role of immune responses across all malignancies,
which in turn will determine the clinical outcomes. In
this sense, a recent study in H4R KO mice show for the
first time the key role of this receptor in the antitumor
immunity in a model of triple-negative breast cancer
(Sterle et al., 2019). Therefore, before moving forward to
clinical trials, pharmacological relevance of specific H4R
agonists must be corroborated in immunocompetent tumor-
bearing animal models.
Considering differences in gene expression levels among
age, gender, ethnic origin, which should also be evaluated at
the protein level, H4R ligands with potential use in clinical
settings need to be evaluated for safety and efficacy in different
ethnic groups, men and women, and children and in various
oncological diseases.
It is worth noting that histamine treatment demonstrated
favorable outcomes in different malignancies. In this regard,
histamine stands out as a promising drug for cancer treatment,
as a single agent or even for its use in combination therapy,
which deserves to be tested in clinical settings. The fact that
histamine is approved to be used in humans reduces the gap
between experimental work and the potential clinical application.
The challenge remains to use generated basic research,
identifying novel molecular targets, for the development of
personalized cancer treatment.
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Golabek, T., Powroźnik, J., Chłosta, P., Dobruch, J., and Borówka, A. (2015). State
of the art paper The impact of nutrition in urogenital cancers. Arch. Med. Sci. 2,
411–418. doi: 10.5114/aoms.2015.50973
Gutting, T., Burgermeister, E., Härtel, N., and Ebert, M. P. (2018). Checkpoints and
beyond – Immunotherapy in colorectal cancer. Semin. Cancer Biol. 55, 78–89.
doi: 10.1016/j.semcancer.2018.04.003
Gutzmer, R., Gschwandtner, M., Rossbach, K., Mommert, S., Werfel, T.,
Kietzmann, M., et al. (2011). Pathogenetic and therapeutic implications of the
histamine H4 receptor in inflammatory skin diseases and pruritus. Front. Biosci.
3, 985–994.
Gutzmer, R., Werfel, T., Bäumer, W., Kietzmann, M., Chazot, P. L., and Leurs, R.
(2012). Well characterized antihistamine 4 receptor antibodies contribute to
current knowledge of the expression and biology of the human and murine
histamine 4 receptor. Naunyn Schmiedebergs Arch. Pharmacol. 385, 853–854.
doi: 10.1007/s00210-012-0744-0
He, G.-H., Ding, J.-Q., Zhang, X., Xu, W.-M., Lin, X.-Q., Huang, M.-J., et al. (2018).
Activation of histamine H4 receptor suppresses the proliferation and invasion of
esophageal squamous cell carcinoma via both metabolism and non-metabolism
signaling pathways. J. Mol. Med. 96, 951–964. doi: 10.1007/s00109-018-1676-z
He, G.-H., Lu, J., Shi, P.-P., Xia, W., Yin, S.-J., Jin, T.-B., et al. (2013).
Polymorphisms of human histamine receptor H4 gene are associated with
breast cancer in Chinese Han population. Gene 519, 260–265. doi: 10.1016/j.
gene.2013.02.020
Hellstrand, K., Brune, M., Naredi, P., Mellqvist, U. H., Hansson, M., Gehlsen, K. R.,
et al. (2000). Histamine: a novel approach to cancer immunotherapy. Cancer
Invest. 18, 347–355.
Hirsch, F. R., Scagliotti, G. V., Mulshine, J. L., Kwon, R., Curran, W. J., Wu, Y.-
L., et al. (2017). Lung cancer: current therapies and new targeted treatments.
Lancet 389, 299–311. doi: 10.1016/S0140-6736(16)30958-8
Ingraffea, A. A., Neal, K. W., Godsey, T., and Gloster, H. M. (2012). Time-
saving tips for processing large, fatty Mohs specimens. Dermatologic Surg. 38,
1540–1541. doi: 10.1111/j.1524-4725.2012.02521.x
Jimenez-Guerrero, R., Gasca, J., Flores, M. L., Perez-Valderrama, B., Tejera-
Parrado, C., Medina, R., et al. (2018). Obatoclax and paclitaxel synergistically
induce apoptosis and overcome paclitaxel resistance in urothelial cancer cells.
Cancers 10:E490. doi: 10.3390/cancers10120490
Jutel, M., Akdis, M., and Akdis, C. A. (2009). Histamine, histamine receptors
and their role in immune pathology. Clin. Exp. Allergy 39, 1786–1800.
doi: 10.1111/j.1365-2222.2009.03374.x
Frontiers in Pharmacology | www.frontiersin.org 13 June 2019 | Volume 10 | Article 556
fphar-10-00556 June 4, 2019 Time: 16:22 # 14
Nicoud et al. H4R a New Target in Cancer Treatment
Kato, H., and Nakajima, M. (2013). Treatments for esophageal cancer: a review.
Gen. Thorac. Cardiovasc. Surg. 61, 330–335. doi: 10.1007/s11748-013-0246-0
Kiffin, R., Grauers Wiktorin, H., Nilsson, M. S., Aurelius, J., Aydin, E.,
Lenox, B., et al. (2018). Anti-leukemic properties of histamine in monocytic
leukemia: the role of NOX2. Front. Oncol. 8:218. doi: 10.3389/fonc.2018.
00218
Kollmeier, A., Francke, K., Chen, B., Dunford, P. J., Greenspan, A. J., Xia, Y.,
et al. (2014). The histamine H4 receptor antagonist, JNJ 39758979, is effective
in reducing histamine-induced pruritus in a randomized clinical study in
healthy subjects. J. Pharmacol. Exp. Ther. 350, 181–187. doi: 10.1124/jpet.114.
215749
Kollmeier, A. P., Barnathan, E. S., O’Brien, C., Chen, B., Xia, Y. K., Zhou, B., et al.
(2018). A phase 2a study of toreforant, a histamine H4 receptor antagonist, in
eosinophilic asthma. Ann. Allergy Asthma Immunol. 121, 568–574. doi: 10.1016/
j.anai.2018.08.001
Leurs, R., Chazot, P. L., Shenton, F. C., Lim, H. D., and De Esch, I. J. P. (2009).
Molecular and biochemical pharmacology of the histamine H4 receptor. Br. J.
Pharmacol. 157, 14–23. doi: 10.1111/j.1476-5381.2009.00250.x
Li, Y., Yang, K., Li, K., Liu, H., Zhao, S., Jiao, M., et al. (2018). Clinical and
molecular characteristics of bladder urothelial carcinoma subtypes. J. Cell Biol.
120, 9956–9963. doi: 10.1002/jcb.28278
Lim, H. D., Adami, M., Guaita, E., Werfel, T., Smits, R. A., De Esch, I. J. P., et al.
(2009). Pharmacological characterization of the new histamine H4 receptor
agonist VUF 8430. Br. J. Pharmacol. 157, 34–43. doi: 10.1111/j.1476-5381.2009.
00200.x
Lin, L., Yamagata, K., Nakayamada, S., Sawamukai, N., Yamaoka, K., Sakata,
K., et al. (2015). Histamine inhibits differentiation of skin fibroblasts into
myofibroblasts. Biochem. Biophys. Res. Commun. 463, 434–439. doi: 10.1016/
j.bbrc.2015.05.094
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., et al. (2008).
Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390.
doi: 10.1056/NEJMoa0708857
Llovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman,
M., et al. (2016). Hepatocellular carcinoma. Nat. Rev. Dis. Prim. 2:16018.
doi: 10.1038/nrdp.2016.18
Martinel Lamas, D. J., Cortina, J. E., Ventura, C., Sterle, H. A., Valli, E., Balestrasse,
K. B., et al. (2015a). Enhancement of ionizing radiation response by histamine
in vitro and in vivo in human breast cancer. Cancer Biol. Ther. 16, 137–148.
doi: 10.4161/15384047.2014.987091
Martinel Lamas, D. J., Croci, M., Carabajal, E., Crescenti, E. J. V., Sambuco, L.,
Massari, N. A., et al. (2013). Therapeutic potential of histamine H4 receptor
agonists in triple-negative human breast cancer experimental model. Br. J.
Pharmacol. 170, 188–199. doi: 10.1111/bph.12137
Martinel Lamas, D. J., Nicoud, M. B., Sterle, H. A., Carabajal, E., Tesan, F., Perazzo,
J. C., et al. (2015d). Selective cytoprotective effect of histamine on doxorubicin-
induced hepatic and cardiac toxicity in animal models. Cell Death Discov.
1:15059. doi: 10.1038/cddiscovery.2015.59
Martinel Lamas, D. J., Nicoud, M. B., Sterle, H. A., Cremaschi, G. A., and Medina,
V. A. (2015b). Histamine: a potential cytoprotective agent to improve cancer
therapy? Cell Death Dis. 6:e2029. doi: 10.1038/cddis.2015.378
Martinel Lamas, D. J., Rivera, E. S., and Medina, V. A. (2015c). Histamine H4
receptor: insights into a potential therapeutic target in breast cancer. Front.
Biosci. 7, 1–9.
Martner, A., Thorén, F. B., Aurelius, J., Söderholm, J., Brune, M., and Hellstrand,
K. (2010). Immunotherapy with histamine dihydrochloride for the prevention
of relapse in acute myeloid leukemia. Expert Rev. Hematol. 3, 381–391.
doi: 10.1586/ehm.10.30
Marzuka, A., Huang, L., Theodosakis, N., and Bosenberg, M. (2015). Melanoma
treatments: advances and mechanisms. J. Cell. Physiol. 230, 2626–2633.
doi: 10.1002/jcp.25019
Massari, N. A., Medina, V. A., Cricco, G. P., Martinel Lamas, D. J., Sambuco, L.,
Pagotto, R., et al. (2013). Antitumor activity of histamine and clozapine in a
mouse experimental model of human melanoma. J. Dermatol. Sci. 72, 252–262.
doi: 10.1016/j.jdermsci.2013.07.012
Massari, N. A., Medina, V. A., Martinel Lamas, D. J., Cricco, G. P., Croci,
M., Sambuco, L., et al. (2011). Role of H4 receptor in histamine-mediated
responses in human melanoma. Melanoma Res. 21, 395–404. doi: 10.1097/
CMR.0b013e328347ee53
Massari, N. A., Nicoud, M. B., and Medina, V. A. (2019). Histamine receptors
and cancer pharmacology: an update. Br. J. Pharmacol. doi: 10.1111/bph.14535
[Epub ahead of print].
Massari, N. A., Nicoud, M. B., Sambuco, L., Cricco, G. P., Lamas, D. J. M., Ducloux,
M. V. H., et al. (2017). Histamine therapeutic efficacy in metastatic melanoma:
role of histamine H4 receptor agonists and opportunity for combination
with radiation. Oncotarget 8, 26471–26491. doi: 10.18632/oncotarget.
15594
Medina, V., Cricco, G., Nuñez, M., Martín, G., Mohamad, N., Correa-Fiz, F.,
et al. (2006). Histamine-mediated signaling processes in human malignant
mammary cells. Cancer Biol. Ther. 5, 1462–1471.
Medina, V., Croci, M., Crescenti, E., Mohamad, N., Sanchez-Jiménez, F., Massari,
N., et al. (2008). The role of histamine in human mammary carcinogenesis: H3
and H4 receptors as potential therapeutic targets for breast cancer treatment.
Cancer Biol. Ther. 7, 28–35.
Medina, V. A., Coruzzi, G., Lamas, D. J. M., Massari, N., Adami, M., Levi-Schaffer,
F., et al. (2013). “Histamine in cancer,” in Histamine H4 Receptor: A Novel Drug
Target in Immunoregulatory and Inflammatory Diseases, ed. H. Stark (London:
Versita), 259–308. doi: 10.2478/9788376560564.c8
Medina, V. A., Prestifilippo, J. P., Croci, M., Carabajal, E., Bergoc, R. M., Elverdin,
J. C., et al. (2011). Histamine prevents functional and morphological alterations
of submandibular glands induced by ionising radiation. Int. J. Radiat. Biol. 87,
284–292. doi: 10.3109/09553002.2010.533247
Medina, V. A., and Rivera, E. S. (2010). Histamine receptors and cancer
pharmacology. Br. J. Pharmacol. 161, 755–767. doi: 10.1111/j.1476-5381.2010.
00961.x
Meng, F., Han, Y., Staloch, D., Francis, T., Stokes, A., and Francis, H.
(2011). The H4 histamine receptor agonist, clobenpropit, suppresses human
cholangiocarcinoma progression by disruption of epithelial mesenchymal
transition and tumor metastasis. Hepatology 54, 1718–1728. doi: 10.1002/hep.
24573
Micallef, S., Stark, H., and Sasse, A. (2013). Polymorphisms and genetic linkage of
histamine receptors. Life Sci. 93, 487–494. doi: 10.1016/j.lfs.2013.08.012
Miyauchi, S., Hirasawa, A., Iga, T., Liu, N., Itsubo, C., Sadakane, K., et al. (2009).
Distribution and regulation of protein expression of the free fatty acid receptor
GPR120. Naunyn Schmiedebergs Arch. Pharmacol. 379, 427–434. doi: 10.1007/
s00210-008-0390-8
Motz, G. T., and Coukos, G. (2013). Deciphering and reversing tumor immune
suppression. Immunity 39, 61–73. doi: 10.1016/j.immuni.2013.07.005
Murata, Y., Song, M., Kikuchi, H., Hisamichi, K., Xu, X. L., Greenspan, A., et al.
(2015). Phase 2a, randomized, double-blind, placebo-controlled, multicenter,
parallel-group study of a H4 R-antagonist (JNJ-39758979) in Japanese adults
with moderate atopic dermatitis. J. Dermatol. 42, 129–139. doi: 10.1111/1346-
8138.12726
Nagini, S. (2017). Breast cancer: current molecular therapeutic targets and new
players. Anticancer Agents Med. Chem. 17, 152–163.
Nijmeijer, S., Vischer, H. F., Rosethorne, E. M., Charlton, S. J., and Leurs, R.
(2012). Analysis of multiple histamine H4 receptor compound classes uncovers
Gαi protein- and β-arrestin2-biased ligands. Mol. Pharmacol. 82, 1174–1182.
doi: 10.1124/mol.112.080911
Paik, W. H., Ryu, J. K., Jeong, K.-S., Park, J. M., Song, B. J., Lee, S. H., et al. (2014).
Clobenpropit enhances anti-tumor effect of gemcitabine in pancreatic cancer.
World J. Gastroenterol. 20, 8545–8557. doi: 10.3748/wjg.v20.i26.8545
Panula, P., Chazot, P. L., Cowart, M., Gutzmer, R., Leurs, R., Liu, W. L. S.,
et al. (2015). International union of basic and clinical pharmacology. XCVIII.
histamine receptors. Pharmacol. Rev. 67, 601–655. doi: 10.1124/pr.114.010249
Perz, J. B., and Ho, A. D. (2008). Histamine dihydrochloride for the treatment of
acute myeloid leukemia, malignant melanoma and renal cell carcinoma. Future
Oncol. 4, 169–177. doi: 10.2217/14796694.4.2.169
Pilleron, S., Sarfati, D., Janssen-Heijnen, M., Vignat, J., Ferlay, J., Bray, F., et al.
(2019). Global cancer incidence in older adults, 2012 and 2035: a population-
based study. Int. J. cancer 144, 49–58. doi: 10.1002/ijc.31664
Prieto, P. A., Reuben, A., Cooper, Z. A., and Wargo, J. A. (2016). Targeted
therapies combined with immune checkpoint therapy. Cancer J. 22, 138–146.
doi: 10.1097/PPO.0000000000000182
Ratnapradipa, K. L., Lian, M., Jeffe, D. B., Davidson, N. O., Eberth, J. M.,
Pruitt, S. L., et al. (2017). Patient, hospital, and geographic disparities
in laparoscopic surgery use among surveillance, epidemiology, and end
Frontiers in Pharmacology | www.frontiersin.org 14 June 2019 | Volume 10 | Article 556
fphar-10-00556 June 4, 2019 Time: 16:22 # 15
Nicoud et al. H4R a New Target in Cancer Treatment
results-medicare patients with colon cancer. Dis. Colon Rectum 60, 905–913.
doi: 10.1097/DCR.0000000000000874
Roth, G. S., and Decaens, T. (2017). Liver immunotolerance and hepatocellular
carcinoma: patho-physiological mechanisms and therapeutic perspectives. Eur.
J. Cancer 87, 101–112. doi: 10.1016/j.ejca.2017.10.010
Rydström, A., Hallner, A., Aurelius, J., Sander, F. E., Bernson, E., Kiffin, R.,
et al. (2017). Dynamics of myeloid cell populations during relapse-preventive
immunotherapy in acute myeloid leukemia. J. Leukoc. Biol. 102, 467–474.
doi: 10.1189/jlb.5VMA1116-455R
Sander, F. E., Nilsson, M., Rydström, A., Aurelius, J., Riise, R. E., Movitz, C., et al.
(2017). Role of regulatory T cells in acute myeloid leukemia patients undergoing
relapse-preventive immunotherapy. Cancer Immunol. Immunother. 66,
1473–1484. doi: 10.1007/s00262-017-2040-9
São Julião, G. P., Habr-Gama, A., Vailati, B. B., Araujo, S. E. A., Fernandez, L. M.,
and Perez, R. O. (2017). New strategies in rectal cancer. Surg. Clin. North Am.
97, 587–604. doi: 10.1016/j.suc.2017.01.008
Schaper-Gerhardt, K., Rossbach, K., Nikolouli, E., Werfel, T., Gutzmer, R., and
Mommert, S. (2019). The role of the histamine H4 receptor in atopic dermatitis
and psoriasis. Br. J. Pharmacol. doi: 10.1111/bph.14550 [Epub ahead of print].
Seifert, R., Schneider, E. H., Dove, S., Brunskole, I., Neumann, D., Strasser, A., et al.
(2011). Paradoxical stimulatory effects of the “standard” histamine H4-receptor
antagonist JNJ7777120: the H4 receptor joins the club of 7 transmembrane
domain receptors exhibiting functional selectivity. Mol. Pharmacol. 79, 631–
638. doi: 10.1124/mol.111.071266
Seifert, R., Strasser, A., Schneider, E. H., Neumann, D., Dove, S., and Buschauer, A.
(2013). Molecular and cellular analysis of human histamine receptor subtypes.
Trends Pharmacol. Sci. 34, 33–58. doi: 10.1016/j.tips.2012.11.001
Song, Z., Wu, Y., Yang, J., Yang, D., and Fang, X. (2017). Progress in the treatment
of advanced gastric cancer. Tumor Biol. 39:1010428317714626. doi: 10.1177/
1010428317714626
Stark, H. (2013). Histamine H4 Receptor?: A Novel Drug Target in
Immunoregulation and Inflammation Versita Discipline?. Warsaw: Versita
Ltd, 13–16.
Sterle, H. A., Nicoud, M. B., Massari, N. A., Táquez Delgado, M. A., Herrero
Ducloux, M. V., Cremaschi, G. A., et al. (2019). Immunomodulatory role of
histamine H4 receptor in breast cancer. Br. J. Cancer 120, 128–138. doi: 10.1038/
s41416-018-0173-z
Stoyanov, E., Uddin, M., Mankuta, D., Dubinett, S. M., and Levi-Schaffer, F. (2012).
Mast cells and histamine enhance the proliferation of non-small cell lung cancer
cells. Lung Cancer 75, 38–44. doi: 10.1016/j.lungcan.2011.05.029
Tamas, K., Walenkamp, A. M. E., de Vries, E. G. E., van Vugt, M. A., Beets-Tan,
R. G., van Etten, B., et al. (2015). Rectal and colon cancer: not just a different
anatomic site. Cancer Treat. Rev. 41, 671–679. doi: 10.1016/j.ctrv.2015.06.007
Tanaka, T., Kochi, T., Shirakami, Y., Mori, T., Kurata, A., Watanabe, N.,
et al. (2016). Cimetidine and clobenpropit attenuate inflammation-associated
colorectal carcinogenesis in male ICR mice. Cancers 8:E25. doi: 10.3390/
cancers8020025
Thun, M. J., DeLancey, J. O., Center, M. M., Jemal, A., and Ward, E. M. (2010). The
global burden of cancer: priorities for prevention. Carcinogenesis 31, 100–110.
doi: 10.1093/carcin/bgp263
Thurmond, R. L. (2015). The histamine H4 receptor: from orphan to the clinic.
Front. Pharmacol. 6:65. doi: 10.3389/fphar.2015.00065
Thurmond, R. L., Chen, B., Dunford, P. J., Greenspan, A. J., Karlsson, L., La,
D., et al. (2014). Clinical and preclinical characterization of the histamine
H4 receptor antagonist JNJ-39758979. J. Pharmacol. Exp. Ther. 349, 176–184.
doi: 10.1124/jpet.113.211714
Thurmond, R. L., Greenspan, A., Radziszewski, W., Xu, X. L., Miao, Y., Chen, B.,
et al. (2016). Toreforant, a histamine H4 receptor antagonist, in patients with
active rheumatoid arthritis despite methotrexate therapy: results of 2 phase II
studies. J. Rheumatol. 43, 1637–1642. doi: 10.3899/jrheum.160164
Thurmond, R. L., Venable, J., Savall, B., La, D., Snook, S., Dunford, P. J., et al.
(2017). Clinical development of histamine H4 receptor antagonists. Handb. Exp.
Pharmacol. 241, 301–320. doi: 10.1007/164_2016_130
van Rijn, R. M., van Marle, A., Chazot, P. L., Langemeijer, E., Qin, Y., Shenton,
F. C., et al. (2008). Cloning and characterization of dominant negative splice
variants of the human histamine H4 receptor. Biochem. J. 414, 121–131. doi:
10.1042/BJ20071583
Vansteenkiste, J., Crinò, L., Dooms, C., Douillard, J. Y., Faivre-Finn, C., Lim, E.,
et al. (2014). 2nd ESMO consensus conference on lung cancer: early-stage non-
small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann.
Oncol. 25, 1462–1474. doi: 10.1093/annonc/mdu089
Walker, R. C., and Underwood, T. J. (2018). Molecular pathways in
the development and treatment of oesophageal cancer. Best Pract.
Res. Clin. Gastroenterol. 36–37, 9–15. doi: 10.1016/J.BPG.2018.
11.013
Wang, Y., Jiang, Y., Ikeda, J.-I., Tian, T., Sato, A., Ohtsu, H., et al. (2014). Roles
of histamine on the expression of aldehyde dehydrogenase 1 in endometrioid
adenocarcinoma cell line. Cancer Med. 3, 1126–1135. doi: 10.1002/
cam4.296
Werfel, T., Layton, G., Yeadon, M., Whitlock, L., Osterloh, I., Jimenez, P., et al.
(2018). Efficacy and safety of the histamine H4 receptor antagonist ZPL-
3893787 in patients with atopic dermatitis. J. Allergy Clin. Immunol. 143,
1830.e–1837.e. doi: 10.1016/j.jaci.2018.07.047
XIao, W., Wang, X., Wang, T., and Xing, J. (2018). TRIM2 downregulation in clear
cell renal cell carcinoma affects cell proliferation, migration, and invasion and
predicts poor patients’ survival. Cancer Manag. Res. 10, 5951–5964.
Xie, S.-H., and Lagergren, J. (2018). Risk factors for oesophageal cancer.
Best Pract. Res. Clin. Gastroenterol. 36-37, 3–8. doi: 10.1016/j.bpg.2018.
11.008
Yang, L. P. H., and Perry, C. M. (2011). Histamine dihydrochloride. Drugs 71,
109–122. doi: 10.2165/11206410-000000000-00000
Yang, X. D., Ai, W., Asfaha, S., Bhagat, G., Friedman, R. A., Jin, G., et al.
(2011). Histamine deficiency promotes inflammation-associated carcinogenesis
through reduced myeloid maturation and accumulation of CD11b+Ly6G+
immature myeloid cells. Nat. Med. 17, 87–95. doi: 10.1038/nm.2278
Yaxley, J. (2016). Urinary tract cancers: an overview for general practice. J. Fam.
Med. Prim. Care 5, 533–538. doi: 10.4103/2249-4863.197258
Young, K., Hughes, D. J., Cunningham, D., and Starling, N. (2018).
Immunotherapy and pancreatic cancer: unique challenges and potential
opportunities. Ther. Adv. Med. Oncol. 101, 27–30. doi: 10.1177/
1758835918816281
Yu, L., Xiang, L., Feng, J., Li, B., Zhou, Z., Li, J., et al. (2018). miRNA-21 and
miRNA-223 expression signature as a predictor for lymph node metastasis,
distant metastasis and survival in kidney renal clear cell carcinoma. J. Cancer
9, 3651–3659. doi: 10.7150/jca.27117
Zhang, C., Xiong, Y., Li, J., Yang, Y., Liu, L., Wang, W., et al. (2012). Deletion
and down-regulation of HRH4 gene in gastric carcinomas: a potential
correlation with tumor progression. PLoS One 7:e31207. doi: 10.1371/journal.
pone.0031207
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Nicoud, Formoso and Medina. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice. No
use, distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 15 June 2019 | Volume 10 | Article 556
